2 Einträge von 2 mit patients bleeding
www.cslbehring.ch
Datum der Indexierung
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia from | phase japan | specialty market | study rviii | with immunoglobulins | patients clinical | products prophylaxis | bleeding breakthrough | rix-fp development | global medicines |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients Product Features Phase Manufacturer Half-life extension Eloctate rFVIII fused to Fc Market Biogen Idec N8-GP BDD FVIII O-linked pegyl n Ph II/III Novo Nordisk BAX 855 FVIII Lys-linked pegyl n Market Baxter 1.1 - 1.5 fold* BAY 94-9027 BDD FVI Bleeding /Surgery Hizentra ® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra ® biweekly New Product Development Market Development Life Cycle Management # Pre-clinical Research Phase I Phase
Text Inhalt Text aus URL
Log Metriken 446029
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia from | phase japan | specialty market | study rviii | with immunoglobulins | patients clinical | products prophylaxis | bleeding breakthrough | rix-fp development | global medicines |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients Product Features Phase Manufacturer Half-life extension Eloctate rFVIII fused to Fc Market Biogen Idec N8-GP BDD FVIII O-linked pegyl n Ph II/III Novo Nordisk BAX 855 FVIII Lys-linked pegyl n Market Baxter 1.1 - 1.5 fold* BAY 94-9027 BDD FVI Bleeding /Surgery Hizentra ® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra ® biweekly New Product Development Market Development Life Cycle Management # Pre-clinical Research Phase I Phase
Text Inhalt Text aus URL
Log Metriken 446029
www.cslbehring.ch
Datum der Indexierung 25.04.2021 00:30:41
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients Product Features Phase Manufacturer Half-life extension Eloctate rFVIII fused to Fc Market Biogen Idec N8-GP BDD FVIII O-linked pegyln Ph II/III Novo Nordisk BAX 855 FVIII Lys-linked pegyln Market Baxter 1.1 - 1.5 fold* BAY 94-9027 BDD FVIII Bleeding /Surgery Hizentra® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra® biweekly New Product Development Market Development Life Cycle Management# Pre-clinical Research Phase I Phase II
Text Inhalt Text aus URL
Log Metriken 563121
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients Product Features Phase Manufacturer Half-life extension Eloctate rFVIII fused to Fc Market Biogen Idec N8-GP BDD FVIII O-linked pegyln Ph II/III Novo Nordisk BAX 855 FVIII Lys-linked pegyln Market Baxter 1.1 - 1.5 fold* BAY 94-9027 BDD FVIII Bleeding /Surgery Hizentra® Japan Partnered Vaccine Programs* Partnered Vaccine Programs* FXIIa Antagonist Hizentra® biweekly New Product Development Market Development Life Cycle Management# Pre-clinical Research Phase I Phase II
Text Inhalt Text aus URL
Log Metriken 563121